Los Angeles Capital Management’s Novavax NVAX Stock Holding History

Los Angeles Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.16K	Sell	757 -75	-9%	-$680	﹤0.01%	2071
2025 Q4	$7.01K	Buy	+832	New	+$6.27K	﹤0.01%	2206
2025 Q3	–	Sell	-19,591	Closed	-$123K	–	1479
2025 Q2	$123K	Buy	+19,591	New	+$130K	﹤0.01%	1239
2024 Q4	–	Sell	-29,112	Closed	-$368K	–	1204
2024 Q3	$368K	Buy	+29,112	New	+$376K	﹤0.01%	948
2022 Q1	–	Sell	-1,438	Closed	-$206K	–	1469
2021 Q4	$206K	Sell	1,438 -1,320	-48%	-$227K	﹤0.01%	1341
2021 Q3	$572K	Sell	2,758 -4,835	-64%	-$1.07M	﹤0.01%	992
2021 Q2	$1.61M	Sell	7,593 -263	-3%	-$48.2K	0.01%	644
2021 Q1	$1.42M	Sell	7,856 -2,205	-22%	-$439K	0.01%	745
2020 Q4	$1.12M	Buy	+10,061	New	+$1.07M	﹤0.01%	887

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's NVAX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Novavax (NVAX) stake by 9% in Q1 2026, selling an estimated $680 and leaving 757 shares worth $6.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Los Angeles Capital Management first reported a position in NVAX in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.61M in Q2 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Los Angeles Capital Management held 757 shares of Novavax worth $6.16K as of Q1 2026.
Los Angeles Capital Management sold 75 Novavax shares in Q1 2026, an estimated $680.
Novavax made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2071 holding.
Los Angeles Capital Management first reported a position in Novavax in Q4 2020 and has held it in 9 quarters since.
Los Angeles Capital Management's Novavax position peaked at $1.61M in Q2 2021.
258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.